11/24
04:15 pm
ibio
iBio to Participate in the 8th Annual Evercore Healthcare Conference
Medium
Report
iBio to Participate in the 8th Annual Evercore Healthcare Conference
11/16
01:09 am
ibio
Medium
Report
11/12
04:27 pm
ibio
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/12
04:01 pm
ibio
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
Medium
Report
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
10/30
07:00 am
ibio
iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
Medium
Report
iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
10/29
07:02 pm
ibio
iBio (NYSE:IBIO) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Neutral
Report
iBio (NYSE:IBIO) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
10/23
07:00 am
ibio
iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
High
Report
iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
10/23
01:59 am
ibio
High
Report
10/21
08:03 am
ibio
iBio (NYSE:IBIO) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $5.00 price target on the stock.
Low
Report
iBio (NYSE:IBIO) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $5.00 price target on the stock.
10/21
07:00 am
ibio
iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025
Medium
Report
iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025
10/18
07:31 am
ibio
iBio (NASDAQ:IBIO) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
iBio (NASDAQ:IBIO) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
10/17
07:02 am
ibio
iBio (NYSE:IBIO) was given a new $2.00 price target on by analysts at Leerink Partners.
Low
Report
iBio (NYSE:IBIO) was given a new $2.00 price target on by analysts at Leerink Partners.
10/15
12:25 pm
ibio
Ibio (NASDAQ:IBIO) is now covered by analysts at
Weiss Ratings. They set a "sell (e+)" rating on the stock.
Medium
Report
Ibio (NASDAQ:IBIO) is now covered by analysts at
Weiss Ratings. They set a "sell (e+)" rating on the stock.
10/15
01:12 am
ibio
Medium
Report
9/5
07:41 am
ibio
iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
9/5
07:30 am
ibio
iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
Low
Report
iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update